Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754183 | 0.90 | HRH3 (0.39) | HRH3MLNR | |
| SCHEMBL4402036 | 0.90 | HRH3 (0.39) | HRH3MLNR | |
| SCHEMBL4402202 | 0.78 | CTSD (0.37) | HRH3MLNR | |
| SCHEMBL12019149 | 0.78 | ITGB3 (0.41) | HRH3MLNR | |
| SCHEMBL4399717 | 0.78 | ITGB3 (0.41) | HRH3MLNR | |
| SCHEMBL15762025 | 0.78 | ITGB3 (0.41) | HRH3MLNR | |
| SCHEMBL16840265 | 0.78 | ITGB3 (0.41) | HRH3MLNR | |
| SCHEMBL19696332 | 0.75 | PRKCD (0.31) | HRH3 | |
| SCHEMBL2672144 | 0.72 | HRH3 (0.40) | HRH3MLNR | |
| SCHEMBL17966438 | 0.72 | HRH3 (0.40) | HRH3MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UWM RESEARCH FOUNDATION, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | HRH3 1934/4885MLNR 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.